MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

(Moderate)

(Positive)

Rhea-AI Summary

MyOme and Natera (NASDAQ: NTRA) launched the Zenith™ portfolio, a premium exome and genome testing solution integrating MyOme's long-read methylation analysis with Natera's clinical network.

Methylation analysis will be automatically added to all eligible rare disease exome and genome orders starting early Q2 2026, initially as targeted confirmation for select conditions.

Positive

Zenith available for commercial orders through Natera
Methylation analysis automatically integrated into eligible orders starting early Q2 2026
Combines long-read sequencing with methylation for multi-omic rare disease diagnostics

Negative

Methylation support initially limited to targeted confirmation for select conditions
Broader disease-area expansion follows a strategic roadmap rather than immediate full coverage

News Market Reaction – NTRA

-3.20%

-3.20% Session close to close

In the Mar 12 session, NTRA declined 3.20%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends Natera’s reach in rare disease diagnostics by debuting the Zenith™ portfol...

Analysis

This announcement extends Natera’s reach in rare disease diagnostics by debuting the Zenith™ portfolio with MyOme and adding long-read methylation analysis to exome and genome testing starting in early Q2 2026. It complements recent initiatives in oncology and women’s health, reinforcing a broader multi-omic strategy. Investors may track adoption through Natera’s clinical network, future data readouts, and how integrated methylation testing affects diagnostic yield and commercial traction.

Key Figures

Diagnostic delay: five-year ACMG 2026 session time: 12:15 PM Exhibit Theater slot: 10:45–11:15 am +1 more

4 metrics

Diagnostic delay five-year Average diagnostic delay for rare disease patients cited in article

ACMG 2026 session time 12:15 PM Corporate Partner Insights Session on March 11 at ACMG 2026

Exhibit Theater slot 10:45–11:15 am MyOme & Natera partnership presentation on March 13 at ACMG 2026

Medical Genetics Awareness Week March 10–14 MyOme sponsorship window mentioned in article

Historical Context

5 past events · Latest: Feb 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 27	Oncology data update	Positive	-3.7%	ASCO GU Signatera MRD data across genitourinary cancers highlighted clinical potential.
Feb 26	Earnings results	Positive	-3.7%	Reported strong Q4 and FY2025 revenue growth, margin expansion, and positive cash flow.
Feb 24	Clinical trial readout	Positive	+0.1%	Phase 2 SINERGY trial showed 63% ORR and reduced chemotherapy exposure in HNSCC.
Feb 17	Earnings date notice	Neutral	+2.4%	Announced timing and access details for upcoming Q4 and full-year 2025 results.
Feb 06	New study launch	Positive	+3.0%	Launched EDEN study to evaluate cfDNA-based test for early preeclampsia risk assessment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: several positive clinical and commercial updates saw both gains and selloffs, including a notable decline after strong Q4/FY25 results.

Recent Company History

Over the past month, Natera reported strong Q4/FY2025 financials with revenue growth and margin expansion, yet the stock fell 3.73% the next day. Positive clinical trial readouts (e.g., Phase 2 SINERGY with a 63% ORR) and new study launches like EDEN drew more balanced reactions, ranging from slight gains to modest losses. Today’s MyOme partnership and Zenith™ launch extend Natera’s genomic footprint, fitting into a pattern of expanding clinical applications across oncology, women’s health, and now rare diseases.

Key Terms

methylation signatures, epigenetic signatures, exome, long-read sequencing, +3 more

7 terms

methylation signatures medical

"By integrating methylation signatures (epigenetic signatures) into its whole-genome platform..."

Methylation signatures are patterns of chemical marks on DNA that act like molecular fingerprints, showing which genes are switched on or off in a cell. Investors care because these patterns can be turned into diagnostic tests, ways to monitor treatment or identify drug targets; clear, reliable signatures can create new revenue streams, speed clinical decisions and affect regulatory approval, making them a potential driver of value in biotech and healthcare companies.

epigenetic signatures medical

"By integrating methylation signatures (epigenetic signatures) into its whole-genome platform..."

Epigenetic signatures are patterns of chemical marks on DNA or the proteins that package it that switch genes on or off without changing the genetic code, like sticky notes on a recipe guiding which steps to follow. Investors care because these patterns can serve as measurable biomarkers for diagnosing disease, predicting treatment response, or selecting patients for trials, creating potential markets for diagnostics, drugs, and precision-medicine services.

exome medical

"Recent meta-analyses confirm that a genome-first approach... over legacy exome methods..."

The exome is the portion of an organism’s genetic code that carries the instructions for making proteins — like the highlighted pages in a huge instruction manual that contain the actual recipes. It matters to investors because many genetic tests, drug targets and diagnostics focus on these protein-making instructions; finding disease-linked changes there can speed development of treatments, reduce research costs, and drive commercial value.

long-read sequencing medical

"multi-omic approach leverages long-read sequencing to simultaneously analyze DNA sequence..."

Long-read sequencing is a laboratory method that reads much longer stretches of DNA at once than older approaches, giving a clearer, more continuous picture of a genome—like reading whole sentences instead of just chopped-up words. For investors, it matters because it can improve accuracy of genetic tests, speed up drug research, reduce costly follow-up testing, and create competitive advantages for companies that develop or use the technology in diagnostics and therapeutics.

imprinting conditions medical

"assist in resolving imprinting conditions when parental samples are missing."

Imprinting conditions are the specific environmental or process settings—such as temperature, timing, chemical exposure or growth environment—that cause durable changes in cells or materials during development or manufacturing. Like the oven settings that determine a cake’s texture, these early conditions can lock in characteristics that affect a product’s performance, safety and consistency. Investors care because uncontrolled or variable imprinting can lead to product variability, regulatory problems or unexpected costs in production and clinical use.

electronic medical records (EMR) technical

"leveraging its extensive electronic medical records (EMR) integration footprint..."

Electronic medical records (EMR) are digital versions of a patient’s paper chart used by clinics and hospitals to record diagnoses, treatments, test results, and prescriptions—think of it as a secure, searchable digital filing cabinet for a patient’s care history. Investors care because EMRs affect how efficiently health providers operate, influence costs, enable or block new services, and carry regulatory and data-security risks that can materially change a healthcare company’s revenue and expenses.

whole-genome platform medical

"integrating methylation signatures... into its whole-genome platform..."

A whole-genome platform is a technology system that reads and analyzes an individual’s complete genetic instruction manual, turning raw DNA data into searchable, interpretable information. For investors it matters because such platforms can drive new diagnostics, drug targets, and personalized treatments—acting like a factory that converts biological raw material into multiple commercial products and recurring data assets, but their value depends on accuracy, scale, regulatory approval, and data privacy safeguards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/12/2026 - 08:00 AM

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. By integrating methylation signatures (epigenetic signatures) into its whole-genome platform, MyOme is moving beyond traditional DNA sequencing to resolve the complex cases that currently contribute to an average five-year diagnostic delay for rare disease patients^[1,2]. Recent meta-analyses confirm that a genome-first approach significantly increases diagnostic yield and clinical utility over legacy exome methods, providing the necessary foundation for MyOme's multi-omic innovations.^[3]

Natera Launches Zenith™ powered by MyOme

In a major step toward expanding patient access, MyOme is highlighting its strategic partnership with Natera (NASDAQ: NTRA) to launch Zenith™ powered by MyOme. Zenith is a premium exome and genome testing solution that brings MyOme's innovative genome-first platform to Natera's industry-leading clinical network.

The Zenith portfolio is available for commercial orders through Natera, bringing Zenith genomics to healthcare providers across the United States, leveraging its extensive electronic medical records (EMR) integration footprint, robust clinical support system and unparalleled experience in high-complexity genomics.

"Rare disease patients and their families endure lengthy and costly diagnostic journeys that often delay care and escalate emotional and financial strain," said Meredith Reichert, Ph.D., senior vice president of commercial and general manager of rare disease at Natera. "By combining MyOme's innovation with Natera's nationwide presence and clinical expertise, Zenith has the potential to transform rare disease diagnostics and provide definitive answers to more families."

The Methylation Advantage

Traditional genetic testing identifies changes in the DNA sequence, but requires separate testing to evaluate epigenetic modifications that dictate how genes are expressed. MyOme's new multi-omic approach leverages long-read sequencing to simultaneously analyze DNA sequence and methylation patterns to look for specific disease-related "epigenetic signatures."

At launch, MyOme will perform targeted confirmation for select conditions, with a strategic roadmap to rapidly expand the list of disease areas available on the platform. This added capability allows clinicians to (1) resolve variants of uncertain significance when a methylation signature is available for a gene and (2) assist in resolving imprinting conditions when parental samples are missing.

"It is increasingly clear that the next frontier in addressing rare diseases involves probing genome function alongside sequence." said Akash Kumar, M.D., Ph.D., chief medical officer at MyOme. "By introducing methylation analysis using long-read sequencing, we are taking an important step for comprehensiveness —one that can detect what standard sequencing approaches might miss on their own."^[4]

Starting in early Q2 2026, methylation analysis will be automatically integrated into all eligible rare disease exome and genome analysis orders.

ACMG 2026 Highlights

MyOme's presence at ACMG 2026 underscores its commitment to the medical genetics community:

Corporate Partner Insights Session: "A New Lens in Rare Disease Diagnostics: Integrating Methylation and WGS for Comprehensive Diagnostics" – Wednesday, March 11, 12:15 PM (Room 341-342).
Exhibit Theater: Scaling the Genome: Elevating Rare Disease Diagnostics, How the MyOme & Natera partnership streamlines the path from sample collection to clinical diagnosis through a unified support ecosystem - Friday, March 13, 10:45 am – 11:15 am (Exhibit Theater 1).
Scientific Poster:
- P207: Development of a Single Sequencing Platform for Variant Detection and Methylation Characterization
Community Leadership: MyOme is the official sponsor of Medical Genetics Awareness Week (March 10–14), supporting the theme "Making a Difference Together."

For more information, visit myome.com/landing/myome-at-acmg.

About MyOme

MyOme is a clinical whole genome analysis company helping families understand their risk for diseases. As a leader in polygenic and AI-based integrative risk modeling, MyOme leverages the power of the whole genome, multianalyte and clinical data for a lifetime of meaningful and actionable insights. These capabilities can dramatically reduce healthcare costs and improve outcomes by catching disease earlier and taking steps to delay or stop their onset. Certified under the Clinical Laboratory Improvement Amendments (CLIA) and certified by the College of American Pathologists (CAP), MyOme is based in Menlo Park, California

References

The Global Commission to End the Diagnostic Odyssey for Children with a Rare Disease. "From Idea to Action: 2024 End of Year Report." https://globalrarediseasecommission.com/pressrelease-2024eoyreport/
Rare Diseases: Individually Rare, Collectively Common. The Lancet Diabetes & Endocrinology, vol. 11, no. 3, 2023.
Pandey, R., et al. "A meta-analysis of diagnostic yield and clinical utility of genome and exome sequencing in pediatric rare and undiagnosed genetic diseases" (2025).
Negi, et al. "Advancing long-read genome assembly and accurate variant calling for rare disease detection." American Journal of Human Genetics (2025).

View original content to download multimedia:https://www.prnewswire.com/news-releases/myome-debuts-zenith-portfolio-with-natera-and-launches-long-read-methylation-analysis-at-acmg-2026-302711880.html

SOURCE MyOme, Inc

FAQ

What is Zenith powered by MyOme and how does it involve Natera (NTRA)?

Zenith is a premium exome and genome testing portfolio offered commercially through Natera (NTRA). According to the company, Zenith pairs MyOme's genome-first platform with Natera's EMR integration, clinical support, and nationwide provider network to expand patient access.

When will MyOme's long-read methylation analysis be integrated into Natera (NTRA) orders?

Methylation analysis will be automatically added to eligible rare disease exome and genome orders starting early Q2 2026. According to the company, this integration applies to orders that meet eligibility criteria and begins in the early second quarter of 2026.

How does MyOme's methylation testing improve rare disease diagnostics for Natera (NTRA) patients?

Methylation testing adds epigenetic signatures to DNA sequence data to resolve complex cases and VUS. According to the company, long-read methylation can clarify imprinting conditions and help interpret variants of uncertain significance when signatures exist.

Will Zenith powered by MyOme cover all rare disease conditions at launch for Natera (NTRA)?

No, at launch methylation will perform targeted confirmation for select conditions rather than full coverage. According to the company, there is a strategic roadmap to expand the list of disease areas over time.

How can clinicians order Zenith tests through Natera (NTRA) and access support?

Clinicians can place commercial orders via Natera's clinical network and EMR integrations. According to the company, Natera offers a unified support ecosystem to streamline sample collection, result delivery, and clinical follow-up for Zenith orders.